Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Troponin | 4 | 2021 | 516 | 1.530 |
Why?
|
Anticholesteremic Agents | 5 | 2023 | 987 | 1.520 |
Why?
|
Atherosclerosis | 7 | 2024 | 3518 | 1.330 |
Why?
|
Lipoprotein(a) | 3 | 2024 | 499 | 1.300 |
Why?
|
Cholesterol, LDL | 10 | 2024 | 2420 | 1.290 |
Why?
|
Cardiovascular Diseases | 13 | 2024 | 15760 | 1.160 |
Why?
|
Chest Pain | 5 | 2019 | 1106 | 1.150 |
Why?
|
Glycopeptides | 3 | 2016 | 220 | 1.010 |
Why?
|
Cholesterol | 4 | 2024 | 2924 | 1.000 |
Why?
|
Oligonucleotides, Antisense | 3 | 2024 | 459 | 0.980 |
Why?
|
Cholesterol, VLDL | 1 | 2024 | 71 | 0.940 |
Why?
|
Triglycerides | 5 | 2024 | 2476 | 0.930 |
Why?
|
Endarterectomy | 2 | 2014 | 195 | 0.910 |
Why?
|
Venous Thromboembolism | 3 | 2021 | 1864 | 0.860 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 3332 | 0.860 |
Why?
|
Myocardial Infarction | 9 | 2024 | 11890 | 0.850 |
Why?
|
Guilt | 1 | 2022 | 96 | 0.770 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2021 | 239 | 0.690 |
Why?
|
Ascorbic Acid Deficiency | 1 | 2019 | 25 | 0.680 |
Why?
|
Judgment | 1 | 2022 | 273 | 0.670 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2020 | 179 | 0.630 |
Why?
|
Pericarditis | 1 | 2019 | 135 | 0.600 |
Why?
|
Ticlopidine | 1 | 2022 | 895 | 0.540 |
Why?
|
Coronary Artery Disease | 4 | 2024 | 6659 | 0.540 |
Why?
|
Troponin I | 3 | 2016 | 638 | 0.500 |
Why?
|
Vascular Surgical Procedures | 3 | 2013 | 1469 | 0.500 |
Why?
|
Apolipoproteins B | 4 | 2024 | 388 | 0.470 |
Why?
|
Alkalosis | 1 | 2013 | 54 | 0.450 |
Why?
|
Cardiovascular System | 1 | 2021 | 850 | 0.450 |
Why?
|
Hypertension, Pulmonary | 2 | 2014 | 1570 | 0.440 |
Why?
|
Antacids | 1 | 2013 | 94 | 0.440 |
Why?
|
Pulmonary Embolism | 3 | 2020 | 2543 | 0.440 |
Why?
|
Atrial Fibrillation | 2 | 2023 | 5209 | 0.430 |
Why?
|
Self Medication | 1 | 2013 | 117 | 0.430 |
Why?
|
Cardiology | 1 | 2024 | 1723 | 0.410 |
Why?
|
Dyslipidemias | 1 | 2020 | 895 | 0.410 |
Why?
|
Risk Assessment | 10 | 2024 | 24102 | 0.410 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2021 | 1311 | 0.390 |
Why?
|
Cardiomyopathies | 1 | 2024 | 1951 | 0.390 |
Why?
|
Risk Factors | 16 | 2024 | 74333 | 0.390 |
Why?
|
Preoperative Period | 1 | 2013 | 555 | 0.380 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 2065 | 0.380 |
Why?
|
Calcium | 1 | 2024 | 5725 | 0.360 |
Why?
|
Venous Thrombosis | 1 | 2020 | 1300 | 0.360 |
Why?
|
Heart-Assist Devices | 1 | 2021 | 1291 | 0.350 |
Why?
|
Guideline Adherence | 1 | 2020 | 2283 | 0.350 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2019 | 1387 | 0.340 |
Why?
|
Lipoproteins | 3 | 2024 | 882 | 0.340 |
Why?
|
Foreign Bodies | 1 | 2013 | 397 | 0.330 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2022 | 3200 | 0.320 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2014 | 615 | 0.320 |
Why?
|
Heart Atria | 1 | 2014 | 1346 | 0.310 |
Why?
|
Liver | 1 | 2023 | 7510 | 0.300 |
Why?
|
Humans | 45 | 2024 | 760613 | 0.280 |
Why?
|
Aged | 18 | 2024 | 169143 | 0.250 |
Why?
|
Middle Aged | 21 | 2024 | 220359 | 0.240 |
Why?
|
Angiopoietins | 1 | 2024 | 85 | 0.230 |
Why?
|
Female | 23 | 2024 | 391246 | 0.220 |
Why?
|
Genome-Wide Association Study | 3 | 2022 | 12628 | 0.220 |
Why?
|
Male | 22 | 2024 | 359718 | 0.210 |
Why?
|
Myocardial Ischemia | 1 | 2013 | 2164 | 0.210 |
Why?
|
Apolipoprotein C-III | 1 | 2024 | 209 | 0.210 |
Why?
|
Heart Ventricles | 1 | 2014 | 3812 | 0.200 |
Why?
|
Treatment Outcome | 10 | 2024 | 64981 | 0.200 |
Why?
|
Echocardiography | 1 | 2014 | 4981 | 0.190 |
Why?
|
Double-Blind Method | 4 | 2024 | 12427 | 0.190 |
Why?
|
Oligonucleotides | 1 | 2024 | 588 | 0.180 |
Why?
|
Subtilisins | 1 | 2020 | 82 | 0.180 |
Why?
|
Alcohol Drinking | 1 | 2013 | 4013 | 0.180 |
Why?
|
Hypertriglyceridemia | 1 | 2024 | 316 | 0.180 |
Why?
|
Endophenotypes | 1 | 2022 | 255 | 0.180 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2024 | 10343 | 0.180 |
Why?
|
Algorithms | 1 | 2020 | 13982 | 0.170 |
Why?
|
Scurvy | 1 | 2019 | 35 | 0.170 |
Why?
|
Heart Failure | 2 | 2021 | 11848 | 0.160 |
Why?
|
Hyperlipidemias | 1 | 2023 | 782 | 0.160 |
Why?
|
Niacin | 1 | 2019 | 119 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2022 | 466 | 0.150 |
Why?
|
Troponin T | 1 | 2022 | 774 | 0.150 |
Why?
|
Time Factors | 5 | 2024 | 40139 | 0.140 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14494 | 0.140 |
Why?
|
Down-Regulation | 1 | 2024 | 2913 | 0.140 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12531 | 0.140 |
Why?
|
Predictive Value of Tests | 6 | 2016 | 15286 | 0.140 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39262 | 0.130 |
Why?
|
Acute Coronary Syndrome | 2 | 2022 | 2365 | 0.130 |
Why?
|
Placebo Effect | 1 | 2019 | 520 | 0.130 |
Why?
|
Adrenomedullin | 1 | 2015 | 85 | 0.120 |
Why?
|
Primary Prevention | 1 | 2023 | 1207 | 0.120 |
Why?
|
Hypercholesterolemia | 1 | 2022 | 1155 | 0.120 |
Why?
|
Drug Discovery | 1 | 2022 | 1057 | 0.120 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2023 | 1716 | 0.120 |
Why?
|
Risk Reduction Behavior | 1 | 2020 | 1109 | 0.110 |
Why?
|
Mineralocorticoids | 1 | 2013 | 38 | 0.110 |
Why?
|
Laxatives | 1 | 2013 | 90 | 0.110 |
Why?
|
Bicarbonates | 1 | 2013 | 292 | 0.100 |
Why?
|
Hypokalemia | 1 | 2013 | 152 | 0.100 |
Why?
|
C-Reactive Protein | 1 | 2024 | 3839 | 0.100 |
Why?
|
Language | 1 | 2021 | 1533 | 0.100 |
Why?
|
Gastritis | 1 | 2013 | 198 | 0.100 |
Why?
|
Prospective Studies | 4 | 2022 | 54306 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 17790 | 0.100 |
Why?
|
Cohort Studies | 3 | 2024 | 41337 | 0.100 |
Why?
|
Adult | 8 | 2024 | 220007 | 0.090 |
Why?
|
Aged, 80 and over | 5 | 2021 | 58980 | 0.090 |
Why?
|
Protein Precursors | 1 | 2015 | 1134 | 0.090 |
Why?
|
Genetic Testing | 1 | 2024 | 3531 | 0.090 |
Why?
|
Disease Management | 1 | 2021 | 2514 | 0.090 |
Why?
|
Diuretics | 1 | 2013 | 613 | 0.090 |
Why?
|
Peptide Fragments | 1 | 2023 | 5132 | 0.090 |
Why?
|
Vomiting | 1 | 2013 | 650 | 0.090 |
Why?
|
Prognosis | 3 | 2023 | 29661 | 0.080 |
Why?
|
Fluid Therapy | 1 | 2013 | 579 | 0.080 |
Why?
|
Organ Size | 1 | 2014 | 2254 | 0.080 |
Why?
|
Adipose Tissue | 1 | 2021 | 3300 | 0.080 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2013 | 571 | 0.080 |
Why?
|
ROC Curve | 1 | 2015 | 3568 | 0.070 |
Why?
|
Risk | 1 | 2019 | 9632 | 0.070 |
Why?
|
Eating | 1 | 2013 | 1539 | 0.070 |
Why?
|
Postoperative Period | 1 | 2011 | 1818 | 0.070 |
Why?
|
Phenotype | 1 | 2024 | 16548 | 0.070 |
Why?
|
Genotype | 1 | 2019 | 12957 | 0.060 |
Why?
|
Registries | 1 | 2021 | 8458 | 0.060 |
Why?
|
Stroke | 2 | 2023 | 9952 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 8055 | 0.060 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2014 | 2128 | 0.050 |
Why?
|
Electrocardiography | 2 | 2016 | 6415 | 0.050 |
Why?
|
Young Adult | 2 | 2023 | 58748 | 0.050 |
Why?
|
Incidence | 1 | 2020 | 21391 | 0.050 |
Why?
|
Ultrasonography | 1 | 2014 | 5961 | 0.050 |
Why?
|
Survival Analysis | 1 | 2013 | 10185 | 0.050 |
Why?
|
Sex Factors | 1 | 2014 | 10546 | 0.040 |
Why?
|
Africa | 1 | 2022 | 706 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15790 | 0.040 |
Why?
|
Hypolipidemic Agents | 1 | 2024 | 626 | 0.040 |
Why?
|
Chronic Disease | 1 | 2014 | 9288 | 0.040 |
Why?
|
Heart Diseases | 1 | 2012 | 2809 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 14661 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 12919 | 0.040 |
Why?
|
Virulence | 1 | 2022 | 1298 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12968 | 0.040 |
Why?
|
Secondary Prevention | 1 | 2024 | 1548 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2014 | 20080 | 0.030 |
Why?
|
Patient Discharge | 2 | 2021 | 3474 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3441 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2022 | 1792 | 0.030 |
Why?
|
Cholesterol, HDL | 1 | 2022 | 1817 | 0.030 |
Why?
|
Multifactorial Inheritance | 1 | 2022 | 1365 | 0.030 |
Why?
|
Pravastatin | 1 | 2015 | 393 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2016 | 1180 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2016 | 80345 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2016 | 1722 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2022 | 2803 | 0.020 |
Why?
|
Patient Admission | 1 | 2016 | 1385 | 0.020 |
Why?
|
Brain Ischemia | 1 | 2022 | 3127 | 0.020 |
Why?
|
Exercise Test | 1 | 2016 | 2128 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8556 | 0.020 |
Why?
|
Emergency Service, Hospital | 2 | 2016 | 7818 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3465 | 0.020 |
Why?
|
Acute Disease | 1 | 2015 | 7268 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5508 | 0.010 |
Why?
|
Up-Regulation | 1 | 2012 | 4122 | 0.010 |
Why?
|
Patient Readmission | 1 | 2016 | 3322 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6544 | 0.010 |
Why?
|
Odds Ratio | 1 | 2012 | 9716 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 12289 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15840 | 0.010 |
Why?
|
Dextrans | 1 | 1954 | 574 | 0.010 |
Why?
|
Blood | 1 | 1954 | 586 | 0.010 |
Why?
|
Concepts
(169)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(53)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_